The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis

Zhongbao Zhou1,2,*
Shiqiang Song3,*
Zhenli Gao3
Jitao Wu2
Jiajia Ma2
Yuanshan Cui2

1School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong, China; 2Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China; 3Department of Urology, Qingdao Chengyang People’s Hospital, Qingdao, Shandong, China

*These authors contributed equally to this work

Aim: We performed a meta-analysis to evaluate the efficacy and safety of dutasteride and finasteride in treating men with androgenetic alopecia (AGA) during a 24-week treatment cycle.

Methods: Randomized controlled trials of dutasteride and finasteride for treating AGA were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were calculated using RevMan v5.3.0. The reference lists of retrieved studies were also investigated.

Results: Three articles including 576 participants which compared dutasteride with finasteride were selected for our analysis. The mean change in total hair count (mean difference [MD], 28.57; 95% CI, 18.75–38.39; P<0.00001), investigator’s assessment of global photographs for the vertex (MD, 0.68; 95% CI, 0.13–1.23; P=0.02) and frontal (MD, 0.63; 95% CI, 0.13–1.13; P=0.01) views, panel global photographic assessment for the vertex (MD, 0.17; 95% CI, 0.09–0.24; P<0.00001) and frontal (MD, 0.25; 95% CI, 0.18–0.31; P<0.00001) views, and subjects’ assessment (MD, 0.56; 95% CI, 0.18–0.94; P=0.003) suggested that dutasteride provided a better efficacy in treating men with AGA compared with finasteride. With regard to the assessment of safety, altered libido (P=0.54), erectile dysfunction (P=0.07), and ejaculation disorders (P=0.58), dutasteride did not show a significant difference compared with finasteride.

Conclusion: Dutasteride seems to provide a better efficacy compared with finasteride in treating AGA. The two drugs appear to show similar rates of adverse reactions, especially in sexual dysfunction.

Keywords: androgenetic alopecia, meta-analysis, randomized controlled trials, dutasteride, finasteride

Introduction

Male androgenetic alopecia (AGA), as the most common type of baldness, is an androgen-dependent inherited hair loss, which has a significant impact on patient’s psychological condition.1,2 Hair loss starts mostly from the hairline on both sides of the forehead and gradually expands upward, eventually leading the hair to fall off at the top of the head.3,4

Testosterone is the main androgen in the circulation, but to exert maximum activity in the hair follicles of the scalp, it must first be converted to dihydrotestosterone (DHT) which is the principal pathogenic androgen of AGA by the catalysis of enzyme 5-alpha reductase (5AR).5 Finasteride, an oral type 2 5-alpha reductase inhibitor (5ARI), has been approved by the US Food and Drug Administration for the treatment of AGA, significantly reversing the process of hair loss and increasing the length and density...
of the targeted hair. Observing related literature on the effectiveness of finasteride in AGA, as many as 30%–45% of participants did not show relief of clinical symptoms which were eventually hard to control. Although hair above the head is no longer shed after the treatment of finasteride, patient’s target for treatment is not only to delay the progression of AGA, but also to increase the amount of the targeted hair and improve patients’ quality of life.

Recently, dutasteride, a dual 5ARI, has been used for the treatment of AGA in the clinic, showing a different mechanism and strong therapeutic effect. Dutasteride may provide an alternative treatment for men with AGA after the inconspicuous efficacy of finasteride. Currently, there is not enough evidence to show the merit and demerit of the two drugs.

We performed a meta-analysis to evaluate the efficacy and safety of dutasteride and finasteride in treating AGA during a 24-week treatment cycle.

Materials and methods

Study design
A systematic review of randomized controlled trials (RCTs) was carried out using the PRISMA checklist.

Search strategy
We searched MEDLINE (1990 to August 2018), EMBASE (1995 to August 2018), and the Cochrane Controlled Trials Register to collect studies investigating dutasteride vs finasteride in treating men with AGA. The search formula was as follows: “dutasteride, finasteride, androgenetic alopecia, and RCT”. The authors were contacted to offer further information from their research if necessary. Furthermore, we also searched the reference list of related articles.

Inclusion criteria and trial selection
RCTs that met the following criteria were included: 1) dutasteride vs finasteride in treating men with AGA; 2) the full-text of study was gettable; and 3) the study provided accurate data that could be analyzed, mainly including the total number of subjects and the valuable results of each indicator. If the identical experiment was published in different journals or at different time, the latest study was included in the meta-analysis. If the same group of researchers studied a group of subjects with multiple experiments, then each study was included. The flow diagram of selection process is shown in Figure 1.

Quality assessment
The Jadad scale was used to evaluate the quality of each study. All the retrieved RCTs were included in the study regardless of the quality score. The methods of quality assessment, including method of patient allocation, concealment of allocation, blinding method, and number lost to follow-up, were used to analyze the quality of individual study. Each study was graded on the basis of guidelines published in the Cochrane Handbook for Systematic Reviews of Interventions v5.3.0. The study was evaluated and classified based on quality assessment criteria: A, satisfied all quality criteria and had a low risk of bias; B, ambiguous about one or more quality criteria and had a moderate risk of bias; or C, barely met the quality criteria and had a high risk of bias. Differences regarding the quality assessment were resolved by discussion among the researchers.

Data extraction
The following information was collected for each study: publication time, name of the first author, patient’s received therapy, capacity of sample, the mean change in total hair count, investigator’s assessment of global photographs for the vertex and frontal views, panel global photographic assessment for the vertex and frontal views, subjects’ assessment, altered libido, erectile dysfunction (ED), and ejaculation disorders.

Statistical analyses and meta-analysis
The data were calculated by using Rev Man v5.3.0 (Cochrane Collaboration, Oxford, UK). We analyzed the change of total hair count, investigator’s assessment of global photographs for the vertex and frontal views, panel global photographic assessment for the vertex and frontal views, and
subjects’ assessment between dutasteride and finasteride in treating men with AGA during a 24-week treatment cycle. In addition, the number of cases of altered libido, ED, and ejaculation disorders was also counted. The mean difference (MD) was used to evaluate continuous outcomes and dichotomous outcomes were assessed by OR. We analyzed comparable data using 95% CIs. The indicator could be characterized as fixed-effects model if \( P > 0.05 \), or otherwise, a random-effects model was used. We analyzed inconsistency using the \( I^2 \) statistic, which reflected the proportion of heterogeneity across trails.

**Results**

**Characteristics of individual studies**

Our search strategy found 76 articles. After scrutinizing their abstracts and titles, we ruled out 66 articles. Of the remaining ten articles, seven articles were excluded due to lack of effective data. Finally, three articles containing three RCTs that analyzed dutasteride vs finasteride in treating men with AGA were included in our study. The baseline characteristics of three studies are summarized in Table 1.

**Quality of the individual studies**

All RCTs showed the randomization and double-blinded processes. All studies performed a calculation to obtain the optimal sample size, and two studies used intention-to-treat analysis. The quality level of each study was A (Table 2). The plot was highly symmetrical and three squares were contained in the large triangle, and no evidence of bias was found (Figure 2).

**Efficacy**

**The mean change in total hair count**

Three RCTs enrolling 576 patients (290 in the dutasteride group and 286 in the finasteride group) contained data on the mean change in total hair count (Figure 3). A random-effects model was used to assess these RCTs, the MD was 28.57 and 95% CI was 18.75–38.39 (\( P < 0.00001 \)). Hence, this result suggested that dutasteride showed significant increase in the total hair count compared with finasteride.

**Investigator’s assessment of global photographs for the vertex and frontal views**

Three RCTs enrolling 576 patients (290 in the dutasteride group and 286 in the finasteride group) contained data on the investigator’s assessment of global photographs (Figure 3). For the vertex views, a random-effects model showed an MD of 0.68 and 95% CI of 0.13–1.23 (\( P = 0.02 \)). At the frontal scalp, the MD was 0.63 and 95% CI was 0.13–1.13 (\( P = 0.01 \)).
This result suggested that dutasteride showed statistical differences in the investigator’s assessment of global photographs for the vertex and frontal views compared with finasteride.

Panel global photographic assessment for the vertex and frontal views
Two RCTs enrolling 504 patients (255 in the dutasteride group and 249 in the finasteride group) (Figure 3) contained data on the panel global photographic assessment. For the vertex views, a fixed-effects model showed that the MD was 0.17 and 95% CI was 0.09–0.24 (P<0.00001). At the frontal scalp, the MD was 0.25 and 95% CI was 0.18–0.31 (P<0.00001). We found significant differences between the dutasteride group and finasteride group in the panel global photographic assessment for the vertex and frontal views.

Subjects’ assessment
Three RCTs enrolling 576 patients (290 in the dutasteride group and 286 in the finasteride group) (Figure 3) contained data on the subjects’ assessment. The heterogeneity test showed P=0.02, so we adopted the random-effects model, the MD was 0.56 and 95% CI was 0.18–0.94 (P=0.003). We found statistical differences between the dutasteride group and finasteride group in the subjects’ assessment.

Safety
Altered libido
Three RCTs involving 576 participants (290 in the dutasteride group and 286 in the finasteride group) (Figure 4) contained data on altered libido. The heterogeneity test showed P=0.18, so we chose the fixed-effects model, the 95% CI was 0.66–2.20 and the OR was 1.12 (P=0.54). The result showed that there were no statistical differences in terms of altered libido between the two groups.

Erectile dysfunction
Two RCTs involving 435 participants contained data on ED (219 in the dutasteride group and 216 in the finasteride group) (Figure 4). A fixed-effects model showed an OR of 1.18 and 95% CI of 0.52–2.68 (P=0.70), which showed no significant differences in the ED between the two groups.

Ejaculation disorders
Two RCTs involving 504 participants contained data on ejaculation disorders. A fixed-effects model revealed an OR of 0.75 and 95% CI of 0.28–2.05 (P=0.58). The result showed that the dutasteride group showed no statistical differences in ejaculation disorders compared with the finasteride group.

Discussion
AGA, a multifactorial skin disease with a complex genetic inheritance, is characterized by a progressive shedding of visible terminal hair.\textsuperscript{18} DHT is the vital pathogenic factor in AGA, which results in miniaturization of hair follicles and conversion of terminal hair into vellus hair.\textsuperscript{4,19} Without treatment, patients will suffer from progressive hair growth.\textsuperscript{20} This clinical trial aimed to elucidate the clinical efficacy of dutasteride in AGA.
### Study or subgroup

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dutasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Finasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean difference IV, random, 95% CI</th>
<th>Year</th>
<th>Mean difference IV, random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsen EA 2006</td>
<td>109.6</td>
<td>24.73</td>
<td>71</td>
<td>75.6</td>
<td>21.28</td>
<td>70</td>
<td>30.0</td>
<td>34.00 (26.39, 41.61)</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>89.6</td>
<td>6.18</td>
<td>184</td>
<td>56.5</td>
<td>5.81</td>
<td>179</td>
<td>36.4</td>
<td>33.10 (31.87, 34.33)</td>
<td>2014</td>
<td></td>
</tr>
<tr>
<td>Dhurat RS 2017</td>
<td>23.1</td>
<td>8.44</td>
<td>35</td>
<td>4.3</td>
<td>12.46</td>
<td>37</td>
<td>33.6</td>
<td>18.80 (13.91, 23.69)</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>290</td>
<td></td>
<td>286</td>
<td>100</td>
<td></td>
<td></td>
<td>28.57 (18.75, 38.39)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2$=68.54, $\chi^2$=31.05, df=2 ($P<0.00001$); $I^2$=94%
Test for overall effect: $Z=5.70 (P<0.00001)$

---

### Study or subgroup

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dutasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Finasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean difference IV, random, 95% CI</th>
<th>Year</th>
<th>Mean difference IV, random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsen EA 2006</td>
<td>1.85</td>
<td>1.01</td>
<td>71</td>
<td>1.21</td>
<td>0.94</td>
<td>70</td>
<td>33.6</td>
<td>0.64 (0.32, 0.96)</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>1.3</td>
<td>0.83</td>
<td>184</td>
<td>1.07</td>
<td>0.87</td>
<td>179</td>
<td>36.5</td>
<td>0.23 (0.05, 0.41)</td>
<td>2014</td>
<td></td>
</tr>
<tr>
<td>Dhurat RS 2017</td>
<td>2.23</td>
<td>0.81</td>
<td>35</td>
<td>0.95</td>
<td>1.18</td>
<td>37</td>
<td>29.9</td>
<td>1.28 (0.81, 1.75)</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>290</td>
<td></td>
<td>286</td>
<td>100</td>
<td></td>
<td></td>
<td>0.68 (0.13, 1.23)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2$=20.21, $\chi^2$=19.44, df=2 ($P<0.0001$); $I^2$=90%
Test for overall effect: $Z=2.42 (P=0.02)$

---

### Study or subgroup

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dutasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Finasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean difference IV, random, 95% CI</th>
<th>Year</th>
<th>Mean difference IV, random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsen EA 2006</td>
<td>1.38</td>
<td>0.93</td>
<td>71</td>
<td>0.83</td>
<td>0.95</td>
<td>70</td>
<td>34.0</td>
<td>0.55 (0.24, 0.86)</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>1.11</td>
<td>0.79</td>
<td>184</td>
<td>0.88</td>
<td>0.81</td>
<td>179</td>
<td>37.5</td>
<td>0.23 (0.07, 0.39)</td>
<td>2014</td>
<td></td>
</tr>
<tr>
<td>Dhurat RS 2017</td>
<td>2.03</td>
<td>0.95</td>
<td>35</td>
<td>0.78</td>
<td>1.16</td>
<td>37</td>
<td>28.5</td>
<td>1.25 (0.76, 1.74)</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>290</td>
<td></td>
<td>286</td>
<td>100</td>
<td></td>
<td></td>
<td>0.63 (0.13, 1.13)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2$=3.63, df=1 ($P=0.06$); $I^2$=88%
Test for overall effect: $Z=2.46 (P=0.01)$

---

### Study or subgroup

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dutasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Finasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean difference IV, fixed, 95% CI</th>
<th>Year</th>
<th>Mean difference IV, fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsen EA 2006</td>
<td>1.01</td>
<td>0.87</td>
<td>71</td>
<td>0.62</td>
<td>0.58</td>
<td>70</td>
<td>10.2</td>
<td>0.39 (0.15, 0.63)</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>0.63</td>
<td>0.41</td>
<td>184</td>
<td>0.49</td>
<td>0.39</td>
<td>179</td>
<td>89.8</td>
<td>0.14 (0.06, 0.22)</td>
<td>2014</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>255</td>
<td></td>
<td>249</td>
<td>100</td>
<td></td>
<td></td>
<td>0.17 (0.09, 0.24)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2$=3.63, df=1 ($P=0.06$); $I^2$=72%
Test for overall effect: $Z=4.16 (P<0.0001)$

---

### Study or subgroup

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dutasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Finasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean difference IV, fixed, 95% CI</th>
<th>Year</th>
<th>Mean difference IV, fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsen EA 2006</td>
<td>0.85</td>
<td>0.79</td>
<td>71</td>
<td>0.51</td>
<td>0.66</td>
<td>70</td>
<td>7.0</td>
<td>0.34 (0.10, 0.58)</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>0.58</td>
<td>0.37</td>
<td>184</td>
<td>0.34</td>
<td>0.26</td>
<td>179</td>
<td>93.0</td>
<td>0.24 (0.17, 0.31)</td>
<td>2014</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>255</td>
<td></td>
<td>249</td>
<td>100</td>
<td></td>
<td></td>
<td>0.25 (0.18, 0.31)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2$=0.62, df=1 ($P=0.43$); $I^2$=0%
Test for overall effect: $Z=7.64 (P<0.00001)$

---

### Study or subgroup

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dutasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Finasteride Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean difference IV, random, 95% CI</th>
<th>Year</th>
<th>Mean difference IV, random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsen EA 2006</td>
<td>2.73</td>
<td>1.07</td>
<td>71</td>
<td>2.55</td>
<td>0.89</td>
<td>70</td>
<td>33.7</td>
<td>0.18 (~0.14, 0.50)</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>3.2</td>
<td>1.12</td>
<td>184</td>
<td>2.5</td>
<td>1.01</td>
<td>179</td>
<td>39.0</td>
<td>0.70 (0.48, 0.92)</td>
<td>2014</td>
<td></td>
</tr>
<tr>
<td>Dhurat RS 2017</td>
<td>2.83</td>
<td>1.01</td>
<td>35</td>
<td>2</td>
<td>0.94</td>
<td>37</td>
<td>27.3</td>
<td>0.83 (0.38, 1.28)</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>290</td>
<td></td>
<td>286</td>
<td>100</td>
<td></td>
<td></td>
<td>0.56 (0.18, 0.94)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2$=8.16, df=2 ($P=0.02$); $I^2$=75%
Test for overall effect: $Z=2.92 (P=0.003) $

---

**Figure 3** Forest plots showing changes in (A) the mean change in total hair count, (B) investigator’s assessment of global photographs for the vertex views, (C) investigator’s assessment of global photographs for the frontal views, (D) panel global photographic assessment for the vertex views, (E) panel global photographic assessment for the frontal views, and (F) subjects’ assessment. **Abbreviation:** IV, inverse variance.
loss with age, eventually leading to passive psychological effects including self-conscious preoccupation, worries about aging, helplessness, and feelings of descending attractiveness. This prompts the need for alternate treatment modality.

5AR can transform testosterone to DHT which is the major androgen involved in the pathological process of male AGA. Therefore, inhibiting the activity of 5AR becomes an important treatment method for AGA. Clinically, both dutasteride and finasteride, as two kinds of 5ARI, have performed certain curative effects. One study discovered that dutasteride was approximately three times more potent than finasteride in inhibiting type 2 5AR and 100 times more potent in inhibiting type 1 5AR. After studying the mechanism of action of two drugs, dutasteride was found to be theoretically more effective than finasteride in treating AGA.

We performed this meta-analysis to evaluate the safety and efficacy of dutasteride and finasteride in treating AGA during a 24-week treatment cycle, and found significant differences between the two drugs for the mean change in total hair count, investigator’s assessment of global photographs for the vertex and frontal views, panel global photographic assessment for the vertex and frontal views, and subjects’ assessment. The result showed that dutasteride was more effective than finasteride in all respects for the treatment of AGA. Besides, current data illustrated that the mean change from baseline in the subjects’ assessment score was significantly higher in the dutasteride than in the finasteride group. However, two RCTs showed that there was no statistical significance in self-assessment of size of vertex spot, hair shedding, and hair quality between the two groups with the exception of hair loss on top of scalp.

Scalp DHT can inhibit the expression of Wnt/β-catenin and generate a passive feedback in notch signaling, which results in miniaturization of the hair follicle. Therefore, lowering scalp DHT levels has become an important step to treat AGA. A related clinical study stated that 0.5 mg/day of dutasteride could lower scalp DHT levels by more than 51%, and 5 mg/day of finasteride could lower scalp DHT levels by −41%. Our results proved the efficacy revealed between the two drugs for the mean change in total hair count, investigator’s assessment of global photographs for the vertex and frontal views, panel global photographic assessment for the vertex and frontal views, and subjects’ assessment. The result showed that dutasteride was more effective than finasteride in all respects for the treatment of AGA. Besides, current data illustrated that the mean change from baseline in the subjects’ assessment score was significantly higher in the dutasteride than in the finasteride group. However, two RCTs showed that there was no statistical significance in self-assessment of size of vertex spot, hair shedding, and hair quality between the two groups with the exception of hair loss on top of scalp.

Scalp DHT can inhibit the expression of Wnt/β-catenin and generate a passive feedback in notch signaling, which results in miniaturization of the hair follicle. Therefore, lowering scalp DHT levels has become an important step to treat AGA. A related clinical study stated that 0.5 mg/day of dutasteride could lower scalp DHT levels by more than 51%, and 5 mg/day of finasteride could lower scalp DHT levels by −41%. Our results proved the efficacy revealed between the two drugs for the mean change in total hair count, investigator’s assessment of global photographs for the vertex and frontal views, panel global photographic assessment for the vertex and frontal views, and subjects’ assessment. The result showed that dutasteride was more effective than finasteride in all respects for the treatment of AGA. Besides, current data illustrated that the mean change from baseline in the subjects’ assessment score was significantly higher in the dutasteride than in the finasteride group. However, two RCTs showed that there was no statistical significance in self-assessment of size of vertex spot, hair shedding, and hair quality between the two groups with the exception of hair loss on top of scalp.

Scalp DHT can inhibit the expression of Wnt/β-catenin and generate a passive feedback in notch signaling, which results in miniaturization of the hair follicle. Therefore, lowering scalp DHT levels has become an important step to treat AGA. A related clinical study stated that 0.5 mg/day of dutasteride could lower scalp DHT levels by more than 51%, and 5 mg/day of finasteride could lower scalp DHT levels by −41%. Our results proved the efficacy revealed between the two drugs for the mean change in total hair count, investigator’s assessment of global photographs for the vertex and frontal views, panel global photographic assessment for the vertex and frontal views, and subjects’ assessment. The result showed that dutasteride was more effective than finasteride in all respects for the treatment of AGA. Besides, current data illustrated that the mean change from baseline in the subjects’ assessment score was significantly higher in the dutasteride than in the finasteride group. However, two RCTs showed that there was no statistical significance in self-assessment of size of vertex spot, hair shedding, and hair quality between the two groups with the exception of hair loss on top of scalp.

Figure 4 Forest plots showing changes in (A) altered libido, (B) erectile dysfunction, and (C) ejaculation disorders. Abbreviation: M–H, Mantel–Haenszel.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dutasteride Events</th>
<th>Total</th>
<th>Finasteride Events</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Odds ratio M–H, fixed, 95% CI</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olsen EA 2006</td>
<td>9</td>
<td>71</td>
<td>3</td>
<td>70</td>
<td>13.6</td>
<td>3.24 (0.84, 12.52)</td>
<td>2006</td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>9</td>
<td>184</td>
<td>12</td>
<td>179</td>
<td>59.5</td>
<td>0.72 (0.29, 1.74)</td>
<td>2014</td>
</tr>
<tr>
<td>Dhurat RS 2017</td>
<td>8</td>
<td>35</td>
<td>7</td>
<td>37</td>
<td>27.0</td>
<td>1.27 (0.41, 3.97)</td>
<td>2017</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>290</td>
<td>286</td>
<td>100</td>
<td></td>
<td>1.21 (0.66, 2.20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>B</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>10</td>
<td>184</td>
<td>10</td>
<td>179</td>
<td>91.5</td>
<td>0.97 (0.39, 2.39)</td>
<td>2014</td>
</tr>
<tr>
<td>Dhurat RS 2017</td>
<td>3</td>
<td>35</td>
<td>1</td>
<td>37</td>
<td>8.5</td>
<td>3.38 (0.33, 34.09)</td>
<td>2017</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>219</td>
<td>216</td>
<td>100</td>
<td></td>
<td>1.18 (0.52, 2.68)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>C</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olsen EA 2006</td>
<td>1</td>
<td>71</td>
<td>2</td>
<td>70</td>
<td>22.4</td>
<td>0.49 (0.04, 5.48)</td>
<td>2006</td>
</tr>
<tr>
<td>Harcha WG 2014</td>
<td>6</td>
<td>184</td>
<td>7</td>
<td>179</td>
<td>77.6</td>
<td>0.83 (0.27, 2.51)</td>
<td>2014</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>255</td>
<td>249</td>
<td>100</td>
<td></td>
<td>0.75 (0.28, 2.05)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
by previous studies, meanwhile emphasizing the status of scalp DHT in the nosogenesis of AGA.

The present study showed that dutasteride and finasteride were relatively well-tolerated. Considering possible sexual dysfunction, mainly including altered libido, ED, and ejaculation disorders, the dutasteride group showed no statistical differences compared with the finasteride group. However, Debruyne et al. found that dutasteride would have a better tolerance and fewer adverse events after a 4-year course of treatment. Andriele et al. reported that long-term use of dutasteride might increase the risk of the progression of prostate cancer. As our study is a meta-analysis of short-term treatment, the above-mentioned views could not be supported. According to the current analysis of the safety of the two drugs, the application of two drugs should be carefully considered for young middle-aged men, especially for patients who are sexually active.

Clinical reports found that 5ARI could independently improve the occurrence rate of ED, but many clinicians believed that the side effects of 5ARI would gradually disappear with ongoing treatment. There is considerable controversy about the severity and duration of ED induced by both drugs. Kaufman et al. found that adverse reactions related to sexual functions most commonly occurred in year 1 of treatment with finasteride and placebo (4.4% vs 2.2%); on the contrary, the incidence of adverse reactions decreased in year 5 (0.6% vs 0% for finasteride and placebo, respectively). Therefore, this may indicate that there was no increase in the incidence of adverse reactions related to sexual functions during the course of long-term finasteride treatment. A Phase III trial followed for 4 years demonstrated that dutasteride therapy was well-tolerated over 4 years, with a general trend toward a reduction in incidence of the most common sexual adverse reactions over time (6.0% in year 1, 1.7% in year 2, 1.4% in year 3, and 0.4% in year 4). The adverse effects on sexual function decreased over time but persisted, which may have a negative impact on the patient’s body and mind. Due to the limitation of follow-up period, more studies are needed to explain this concept.

Above all, dutasteride seems to provide a better efficacy compared with finasteride, and two drugs appear to show similar rates of adverse reactions, especially with respect to sexual dysfunction. In terms of dosage, there is no uniform fixation for both drugs at present. Clinically, dutasteride (0.5 mg per day) and finasteride (1 mg per day) have been used by some doctors to treat AGA and have showed good therapeutic effect. Further clinical studies are needed to explain the effect of different dosage of drugs in treating AGA.

Our meta-analysis involved three RCTs and the quality of each RCT was high. We could not infer the long-term efficacy and tolerance of dutasteride and finasteride, and selection bias and publication bias may affect the final results of our study. So, it still needs a lot of substitution of head-to-head comparison to confirm our findings. More high-quality RCTs with suitable study cohorts are needed to ascertain the efficacy and tolerance of dutasteride and finasteride for the treatment of AGA.

Conclusion
Dutasteride seems to provide a better efficacy compared with finasteride in treating AGA. The two drugs appear to show similar rates of adverse reactions, especially with respect to sexual dysfunction.

Acknowledgments
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions
All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References


